Plain-English translation of NCT06549595 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called paired with rituximab, a standard treatment used for lymphoma. Researchers want to see if this combination works better and is safer than the chemotherapy-based treatments currently used as first-line therapy. You would be randomly assigned to receive either the new medication with rituximab (using one of two different schedules) or one of three standard chemotherapy combinations, depending on what your doctor recommends.
Follicular lymphoma is a slow-growing cancer of the immune system, but it still needs treatment. Doctors want to find gentler, more effective options than traditional chemotherapy, especially for people receiving treatment for the first time.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three treatment groups. If you receive the new medication, you'll take it along with rituximab infusions on one of two schedules. If assigned to the comparison group, you'll receive one of three standard chemotherapy combinations chosen by your doctor, also with rituximab. Throughout the study, you'll have regular clinic visits for blood tests, scans, and monitoring to check how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States